Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation.

Shaun P Forbes¹, Elifnur Yay Donderici¹, Nicole Zhang¹, Victoria M Raymond², Amar K Das¹, Peter S Liang^3,4

¹AI and Translational Medicine, Guardant Health Inc, Palo Alto, CA, USA.

²Screening Medical Affairs, Guardant Health Inc, Palo Alto, CA, USA.

³Division of Gastroenterology, NYU Grossman School of Medicine, New York, NY, USA.

⁴Department of Medicine, VA New York Harbor Health Care System, New York, NY, USA.

PubMed DOI

Abstract

AIM: Inadequate adherence to colorectal cancer screening reduces individual and population level health benefits. Blood-based tests offer a new modality that may help patients overcome barriers, but there are concerns about the impact of patients switching from existing guideline-recommended screening modalities. This study estimates the population health outcomes and cost-effectiveness of offerin…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.